NeoGenomics stock gets higher outlook after strong Q3 growth
Published on 11/12/2026 at 03:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQ3 Momentum And Next Steps
- Clinical testing continued to lead the business, supported by demand for higher-value oncology services.
- Coverage expansion for RaDaR ST and new payer agreements broadened reimbursement potential.
- Warren Stone is scheduled to become chief executive in January 2027.
NeoGenomics reported stronger third-quarter operating performance and raised its full-year outlook in an investor release published on October 28, 2026. Revenue increased as clinical testing and next-generation sequencing gained traction, while the GAAP net loss narrowed from the prior-year quarter.
Higher-Value Testing Lifts Results
Revenue for the period ended September 30 rose 11 percent to USD 209 million, according to the NeoGenomics investor release. Clinical revenue grew 13 percent to USD 195 million, with NGS revenue up 29 percent. Clinical volume increased 2 percent, while average revenue per clinical test rose 11 percent to USD 530.
GAAP gross margin expanded to 46 percent from 43 percent a year earlier. Adjusted gross margin reached 49 percent, and adjusted EBITDA rose 53 percent to USD 19 million. The GAAP net loss narrowed to USD 8 million from USD 27 million, while adjusted net income reached USD 11 million.
NeoGenomics stock traded at 15.35 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 11, 2026. The quote gives investors a late-session euro reference for the US-listed company.
Guidance Moves Higher
NeoGenomics lifted its full-year 2026 revenue guidance to USD 807 million to USD 809 million from USD 802 million to USD 806 million previously. Adjusted EBITDA guidance moved to approximately USD 60 million, while the projected net loss range narrowed to USD 30 million to USD 32 million.
The company also expanded Medicare coverage for its RaDaR ST test to include immunotherapy treatment-response monitoring in late-stage solid tumors. NeoGenomics said the indication is the third Medicare-covered use for RaDaR ST and highlighted additional agreements with commercial payers.
Leadership Transition Ahead
President and Chief Operating Officer Warren Stone is scheduled to become chief executive and join the board on January 4, 2027. Current chief executive Tony Zook is then expected to become executive chairman, with the company stating that its strategy will remain focused on higher-value oncology testing and operational efficiency.
Oncology Diagnostics Business
NeoGenomics is a cancer diagnostics company headquartered in Fort Myers, Florida. It provides cancer genetics testing, predictive testing and information services to oncologists, pathologists, hospital systems, academic medical centers and pharmaceutical firms. Its laboratory network spans the United States and includes a full-service sample-processing laboratory in Cambridge, England, giving the company a specialized oncology position within the broader diagnostics industry.
NeoGenomics Stock Facts
- Company: NeoGenomics, Inc.
- ISIN: US64049M2098
- Ticker: NEO
- Home exchange: Nasdaq
- Lang & Schwarz price: 15.35 euros on November 11, 2026, at 11:00 p.m. CET
- Change: plus 0.01 euro, or plus 0.07 percent, from the previous Lang & Schwarz close
The S&P 500 provides the broad US equity market backdrop for NeoGenomics stock.
